Summarized by Masters of Longevity from PR Newswire.
Company completed ATR-04 Cohort 1 and broadened trial to include KRAS and MEK rashes.
Key Takeaways
- Azitra completed Cohort 1 of the ATR-04 Phase 1/2 trial.
- Trial eligibility was expanded to include KRAS and MEK inhibitor rashes.
- Laboratory studies showed ATR-COSF reduced fine lines and improved elasticity.
